- Home
- GLTO vs POLA Comparison
GLTO vs POLA Comparison
Compare GLTO & POLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- POLA
- Stock Information
- Founded
- GLTO 2011
- POLA 1979
- Country
- GLTO Denmark
- POLA United States
- Employees
- GLTO N/A
- POLA N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- POLA Industrial Machinery/Components
- Sector
- GLTO Health Care
- POLA Miscellaneous
- Exchange
- GLTO Nasdaq
- POLA Nasdaq
- Market Cap
- GLTO 4.5M
- POLA 5.3M
- IPO Year
- GLTO 2020
- POLA 2016
- Fundamental
- Price
- GLTO $3.34
- POLA $1.91
- Analyst Decision
- GLTO Buy
- POLA
- Analyst Count
- GLTO 1
- POLA 0
- Target Price
- GLTO $10.00
- POLA N/A
- AVG Volume (30 Days)
- GLTO 19.6K
- POLA 16.9K
- Earning Date
- GLTO 08-05-2025
- POLA 08-14-2025
- Dividend Yield
- GLTO N/A
- POLA N/A
- EPS Growth
- GLTO N/A
- POLA N/A
- EPS
- GLTO N/A
- POLA N/A
- Revenue
- GLTO N/A
- POLA $11,967,000.00
- Revenue This Year
- GLTO N/A
- POLA N/A
- Revenue Next Year
- GLTO N/A
- POLA N/A
- P/E Ratio
- GLTO N/A
- POLA N/A
- Revenue Growth
- GLTO N/A
- POLA 0.14
- 52 Week Low
- GLTO $2.01
- POLA $1.53
- 52 Week High
- GLTO $14.88
- POLA $4.69
- Technical
- Relative Strength Index (RSI)
- GLTO 45.88
- POLA 49.88
- Support Level
- GLTO $3.26
- POLA $1.79
- Resistance Level
- GLTO $3.48
- POLA $2.26
- Average True Range (ATR)
- GLTO 0.15
- POLA 0.13
- MACD
- GLTO -0.00
- POLA -0.01
- Stochastic Oscillator
- GLTO 51.52
- POLA 51.11
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About POLA Polar Power Inc.
Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, backup DC generators, hybrid power systems, Li-Ion battery systems, Marine DC generators, and others. The company's geographical presence is in the United States, Canada, Australia and South Pacific Islands, Asia, Europe and Middle East, United Kingdom, Other North America, South Africa, and others.